Markets:

Overview

News

Currencies

International

Treasuries

DaVita HealthCare Partner (NY:DVA)

181.82 +2.57 (+1.43%)

Delayed Quote Updated: 12:13 PM EDT, Oct 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about DaVita HealthCare Partner

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Sell These 3 Stocks and Kick These Overpaid CEOs Out of Your Portfolio ↗

December 20, 2022

Now is the time to cut your losses on some of your 2022 losers. Here are three stocks to sell whose CEOs didn’t earn their keep.

Via InvestorPlace

Siemens Healthineers, GE Healthcare Studying Potential Deals With Medtronic's Spun Off Units ↗

December 15, 2022

Via Benzinga

If You Invested $100 In This Stock 20 Years Ago, You Would Have $900 Today ↗

December 07, 2022

Via Benzinga

Warren Buffett Now Owns 20% or More of These 5 Companies ↗

November 22, 2022

Which are these big Buffett bets are the best picks for investors?

Via The Motley Fool

$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,500 Today ↗

November 21, 2022

Via Benzinga

$1000 Invested In DaVita 20 Years Ago Would Be Worth This Much Today ↗

November 04, 2022

DaVita (NYSE:DVA) has outperformed the market over the past 20 years by 3.82% on an annualized basis producing an average annual return of 11.29%. Currently, DaVita has a market capitalization of $6.29...

Via Benzinga

DaVita (DVA) Q3 2022 Earnings Call Transcript ↗

October 28, 2022

DVA earnings call for the period ending September 30, 2022.

Via The Motley Fool

DaVita Earnings Perspective: Return On Capital Employed ↗

November 03, 2022

Pulled from Benzinga Pro data, DaVita (NYSE:DVA) showed a loss in earnings since Q2, totaling $164.69 million. Sales, on the other hand, increased by 0.75% to $2.95 billion during Q3.

Via Benzinga

Around $134 Million Bet On This Stock Up 46% Year-To-Date? 3 Stocks Insiders Are Buying ↗

November 02, 2022

Although US stocks closed lower on Tuesday, there were a few notable insider trades.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

October 31, 2022

During Monday's session, 96 stocks hit new 52-week lows.

Via Benzinga

Analyst Ratings for DaVita ↗

October 31, 2022

Over the past 3 months, 5 analysts have published their opinion on DaVita (NYSE:DVA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022 ↗

October 31, 2022

Upgrades

Via Benzinga

Chevron To Rally Around 21%? Here Are 5 Other Price Target Changes For Monday ↗

October 31, 2022

Raymond James raised Chevron Corporation (NYSE: CVX) price target from $188 to $215. Raymond James analyst Justin Jenkins maintained the stock with an Outperform rating. Chevron shares fell 1.1% to...

Via Benzinga

Weibo, XPeng, Li Auto And Other Big Losers From Friday ↗

October 31, 2022

U.S. stocks closed higher on Friday, with the Dow Jones gaining more than 800 points. Here is the list of some big stocks recording losses in the previous session.

Via Benzinga

Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday ↗

October 31, 2022

Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday.

Via Benzinga

Nasdaq Climbs 275 Points; S&P 500 Rises Over 2% ↗

October 28, 2022

U.S. stocks extended gains toward the end of trading, with the Nasdaq Composite surging more than 200 points on Friday.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 28, 2022

Gainers

Via Benzinga

$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today ↗

October 28, 2022

DaVita (NYSE:DVA) has outperformed the market over the past 20 years by 4.09% on an annualized basis producing an average annual return of 11.52%. Currently, DaVita has a market capitalization of $6.63...

Via Benzinga

Dow Jumps 600 Points; Crude Oil Down Over 1% ↗

October 28, 2022

U.S. stocks extended gains midway through trading, with the Dow Jones surging more than 600 points on Friday.

Via Benzinga

2 Market-Moving Stocks You Can't Afford to Ignore ↗

October 28, 2022

Friday's market action saw volatility both upward and downward.

Via The Motley Fool

Why Edwards Lifesciences Shares Are Trading Lower By Around 17%? Here Are 47 Stocks Moving In Friday's Mid-Day Session ↗

October 28, 2022

Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) surged 179% to $3.6301.

Via Benzinga

US Stocks Mostly Higher; Dow Surges 300 Points ↗

October 28, 2022

U.S. stocks traded mostly higher this morning, with the Dow Jones surging more than 300 points on Friday.

Via Benzinga

Dialysis Provider DaVita Slashes FY22 Earnings Outlook Citing Continued Pandemic Impact, Shares Fall ↗

October 28, 2022

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 28, 2022

Gainers Nuvalent (NASDAQ:NUVL) stock increased by 15.9% to $25.5 during Friday's pre-market session. The company's market cap stands at $1.2 billion.

Via Benzinga

Recap: DaVita Q3 Earnings ↗

October 28, 2022

DaVita (NYSE:DVA) reported its Q3 earnings results on Friday, October 28, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings DaVita missed estimated earnings by...

Via Benzinga

Earnings Scheduled For October 28, 2022 ↗

October 28, 2022

Companies Reporting Before The Bell • TAL Education (NYSE:TAL) is projected to report quarterly earnings at $0.01 per share on revenue of $242.62 million.

Via Benzinga

DaVita's Earnings: A Preview ↗

October 27, 2022

DaVita (NYSE:DVA) is set to give its latest quarterly earnings report on Friday, 2022-10-28. Here's what investors need to know before the announcement. Analysts estimate that DaVita will report an...

Via Benzinga

7 Warren Buffett Stocks to Buy and Hold for the Next Decade ↗

October 17, 2022

Intelligent investors know that purchasing Warren Buffett stocks to buy and hold will work in the long-term.

Via InvestorPlace

Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells

October 12, 2022

You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick?

Via TheNewswire.com

Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells ↗

October 11, 2022

You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick?

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.